BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET. Interested parties can access live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com.
This conference provides a platform for BioStem to showcase its advanced allograft solutions and proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®. These technologies are designed to preserve the natural properties of perinatal tissues for clinical use across various medical specialties. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem's portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™. The company's participation in the Needham conference underscores its commitment to advancing innovation in regenerative medicine and expanding its national commercial footprint. For more information, visit biostemtechnologies.com and follow on X and LinkedIn.
The presentation offers an opportunity for investors and industry observers to learn about BioStem's growth strategy, product pipeline, and clinical research initiatives. The virtual format allows broad access to the company's updates. The conference is a key event for healthcare and biotechnology companies to connect with the investment community.
